Vertex Pharmaceuticals Inc. and Alpine Immune Sciences Inc., a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.   The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter. Bringing Povetacicept to Patients Faster Alpine’s...